Together with the parental A-375 [A375] (ATCC® CRL-1619™) cells, these isogenic cell lines can be used for anti-cancer drug discovery and development. This pair of cell lines provides an ideal model for screening novel BRAF specific inhibitors that can overcome drug resistance. It also can be used in RAS-RAF-MEK-ERK (MAPK) signaling pathway studies and to study drug resistance mechanisms in human melanoma.
Mutations in BRAF lead to excessive cellular proliferation, differentiation, and survival. The BRAF V600E mutation occurs in approximately 40% to 50% of melanomas. Although current BRAF inhibitors have been used as therapeutics to treat melanomas, patients often become resistant to the drugs several months after treatment. One mechanism of resistance to these inhibitors is caused by an acquired secondary KRAS mutation. ATCC® CRL-1619IG-1 ™ and ATCC® CRL-1619IG-2 ™ were created at ATCC utilizing the CRISPR/Cas9 gene editing system to generate KRAS G13D and NRAS Q61K mutations respectively, within the A375 melanoma cell line, which naturally harbors the BRAF V600E mutation.
|Date Created||09/28/2017 03:39 PM
|Date Updated||09/28/2017 03:39 PM